| Snowflake Score | |
|---|---|
| Valuation | 2/6 |
| Future Growth | 0/6 |
| Past Performance | 5/6 |
| Financial Health | 5/6 |
| Dividends | 3/6 |
Sam-A Pharm. Co., Ltd Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | ₩23,550.00 |
| 52 Week High | ₩37,950.00 |
| 52 Week Low | ₩15,220.00 |
| Beta | 0.40 |
| 11 Month Change | -34.40% |
| 3 Month Change | 21.45% |
| 1 Year Change | 38.69% |
| 33 Year Change | 39.76% |
| 5 Year Change | 55.96% |
| Change since IPO | 212.38% |
Recent News & Updates
Earnings Working Against Sam-A Pharm. Co., Ltd's (KOSDAQ:009300) Share Price Following 34% Dive
Aug 25
Sam-A Pharm. Co., Ltd's (KOSDAQ:009300) Price Is Right But Growth Is Lacking After Shares Rocket 32%
Jul 11Should You Be Adding Sam-A Pharm (KOSDAQ:009300) To Your Watchlist Today?
Jun 21Recent updates
Earnings Working Against Sam-A Pharm. Co., Ltd's (KOSDAQ:009300) Share Price Following 34% Dive
Aug 25Sam-A Pharm. Co., Ltd's (KOSDAQ:009300) Price Is Right But Growth Is Lacking After Shares Rocket 32%
Jul 11Should You Be Adding Sam-A Pharm (KOSDAQ:009300) To Your Watchlist Today?
Jun 21Sam-A Pharm. Co., Ltd's (KOSDAQ:009300) Shares Bounce 26% But Its Business Still Trails The Market
May 25Key Things To Consider Before Buying Sam-A Pharm. Co., Ltd (KOSDAQ:009300) For Its Dividend
Apr 08Is Sam-A Pharm (KOSDAQ:009300) A Risky Investment?
Mar 04How Much Did Sam-A Pharm's(KOSDAQ:009300) Shareholders Earn From Share Price Movements Over The Last Three Years?
Jan 28
Four Days Left To Buy Sam-A Pharm. Co., Ltd (KOSDAQ:009300) Before The Ex-Dividend Date
Dec 24Sam-A Pharm. Co., Ltd (KOSDAQ:009300) Is Yielding 1.6% - But Is It A Buy?
Dec 07Shareholder Returns
| A009300 | KR Pharmaceuticals | KR Market | |
|---|---|---|---|
| 7D | -7.1% | 1.3% | -0.2% |
| 1Y | 38.7% | 13.3% | 4.1% |
Return vs Industry: A009300 exceeded the KR Pharmaceuticals industry which returned 13.3% over the past year.
Return vs Market: A009300 exceeded the KR Market which returned 4.1% over the past year.
Price Volatility
| A009300 volatility | |
|---|---|
| A009300 Average Weekly Movement | 13.3% |
| Pharmaceuticals Industry Average Movement | 6.4% |
| Market Average Movement | 6.5% |
| 10% most volatile stocks in KR Market | 12.2% |
| 10% least volatile stocks in KR Market | 3.4% |
Stable Share Price: A009300's share price has been volatile over the past 3 months.
Volatility Over Time: A009300's weekly volatility has increased from 8% to 13% over the past year.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 1945 | 295 | Heo Jun | www.samapharm.co.kr |
Sam-A Pharm. Co., Ltd operates as a pharmaceutical company in South Korea. The company offers a range of pharmaceutical products in the areas of respiratory, antibiotics, anti-virals, anti-histamines, anti-fungals, dermatology, pain/inflammation, gastrointestinal, cardiovascular, metabolism, urological, and steroids, as well as psychotropic agents; and OTC products in the areas of respiratory, ant-analgesics, gastro-intestinal, topical, oral, and anti-histamines. It provides NOMA MEGAFFECT for stress relief, eye care, memory and blood lipid concentration enhancement, endurance enhancement, and the supply of vitamins and minerals; and NOMA-F gummy, NOMA CHEWABLE tablet, and NOMA GOLD chewable tablet for growth promotion, enhancement of nutritional deficiency, and supply of vitamins.
Sam-A Pharm. Co., Ltd Fundamentals Summary
| A009300 fundamental statistics | |
|---|---|
| Market cap | ₩143.73b |
| Earnings (TTM) | ₩23.94b |
| Revenue (TTM) | ₩102.51b |
6.0x
P/E Ratio1.4x
P/S RatioIs A009300 overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| A009300 income statement (TTM) | |
|---|---|
| Revenue | ₩102.51b |
| Cost of Revenue | ₩36.83b |
| Gross Profit | ₩65.68b |
| Other Expenses | ₩41.74b |
| Earnings | ₩23.94b |
Last Reported Earnings
Mar 31, 2024
Next Earnings Date
n/a
| Earnings per share (EPS) | 3.92k |
| Gross Margin | 64.07% |
| Net Profit Margin | 23.35% |
| Debt/Equity Ratio | 1.8% |
How did A009300 perform over the long term?
See historical performance and comparison